Flow of a BE trial.
The lifecycle is often shorter than a Phase 3 trial but unforgiving: every step should remain traceable enough to hold under regulator review or inspection years later.
Flow of a BE trial.
Operational pipeline · protocol → submissionThe lifecycle is often shorter than a Phase 3 trial but unforgiving: every step should remain traceable enough to hold under regulator review or inspection years later.
Protocol design & statistical plan.
Study design selection (2×2 crossover, replicate, parallel), sample-size calculation under Schuirmann TOST, washout, fed/fasted scheme. SAP locked before unblinding. Choice anchors the entire submission.
Site qualification & regulator notification.
Phase I unit selection considers volunteer recruitment capacity, bioanalytical logistics, inspection history, and local ethics requirements. Regulatory notification or trial-application needs vary by jurisdiction and study design and should be checked before site activation.
Bioanalytical method validation.
ICH M10 full validation: selectivity, accuracy & precision, calibration curve, matrix effect, stability, dilution integrity. Method readiness should be confirmed before first sample analysis.
Healthy volunteer enrolment.
Screening (PE, ECG, labs, drug-of-abuse). Informed consent. ANVISA volunteer registry check (Brazil). Replacement strategy defined if dropouts occur.
Dosing & sample collection.
Period 1 dosing, washout, Period 2 dosing (crossover) or replicate. Dense PK sampling around Cmax; tail sampling to support AUC0–t and lambda-z estimation. Chain of custody from cannula to freezer.
Bioanalytical sample analysis.
LC-MS/MS quantification under a validated method. Run acceptance criteria, calibration/QC performance, incurred sample reanalysis where required by guidance or protocol, and out-of-trend investigations should be documented and audit-ready.
PK parameter derivation.
Non-compartmental analysis: Cmax (observed), AUC0–t (linear-up/log-down), AUC∞ (extrapolated), tmax, t½, lambda-z. Outlier handling per pre-specified rules. No post-hoc parameter substitution.
Statistical analysis.
Log-transformed ANOVA with sequence, period, subject(sequence), treatment terms. 90% CI of T/R geometric mean ratio for AUC and Cmax. RSABE scaling if HV (FDA) or Cmax-only widening (EMA/ANVISA). NTI tightening if applicable.
Clinical study report.
ICH E3-structured CSR. Bioanalytical report appendix (ICH M10 compliant). Statistical analysis appendix. Volunteer narratives for dropouts, adverse events, protocol deviations.
Module 5 compilation.
CTD Module 5.3.1 BE study reports. Cross-reference Module 3 (CMC, dissolution f2, formulation), Module 2.7 (clinical summary). Reference-product source documentation per jurisdiction.
Submission & regulator dialogue.
ANDA, EU generic pathway, Brazil generic/similar pathway, or WHO PQ submission as applicable. BE-specific questions commonly focus on bioanalytical robustness, reference sourcing, statistical assumptions, NTI/HV designation, and data integrity.
Inspection readiness.
Clinical and bioanalytical inspection readiness should be maintained for applicable authorities. Source documents, raw chromatograms, freezer logs, method records, and audit trails should remain traceable to the dossier.
Official source register.
Regulator / ICH anchorsICH M13A bioequivalence guideline.
Official FDA-hosted page for ICH M13A on bioequivalence for immediate-release solid oral dosage forms. Use as the first harmonised anchor for conventional oral IR BE framing.
BCS-based biowaiver guidance.
Official ICH M9 Step 4 guideline. Use for BCS classification, solubility/permeability thinking, and eligible biowaiver conditions.
Bioanalytical method validation and study sample analysis.
Official ICH M10 Step 4 guideline. Use for the bioanalytical evidence layer that supports BA/BE concentration data.
Product-specific guidances for generic development.
FDA product-specific guidance collection. Use before protocol lock because product-level recommendations can change design, fed/fasted, analyte, and BE expectations.
US bioavailability and bioequivalence regulation.
Electronic Code of Federal Regulations anchor for US BA/BE definitions and requirements. Use for statutory/regulatory context, not as a complete study-design manual.
Guideline on the investigation of bioequivalence.
EMA scientific guideline landing page for BE investigation. Use for EU framing, while checking product-specific or updated procedural context where relevant.
Multisource generic products and interchangeability.
WHO IRIS record for multisource pharmaceutical product guidance. Use as a WHO anchor for generic interchangeability and BE expectations in broader access settings.